Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin vs Empagliflozin for NAFLD in Type 2 Diabetes
NCT07363707Phase 4Completed
- Sponsor
- Beni Suef University
- Start
- May 2023
- Primary completion
- Aug 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of dapagliflozin, empagliflozin in non-alcoholic fatty liver disease (NAFLD), sponsored by Beni Suef University. Started May 2023; status: completed.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT07363707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07363707.